‘The perfect storm’: Why it’s taking a huge toll on Americans

WASHINGTON — It was the perfect storm for the $20 billion-plus rollout of a new life-saving oxygen meter, which would have saved tens of thousands of lives, but also caused a cascade of lawsuits.

The lawsuits and the price tag have driven up the price, with the government paying more than $5 billion to settle claims by more than 10 million Americans, according to government documents obtained by The Associated Press.

In all, nearly half the lawsuits have been settled.

It was only a matter of time before the cost would outstrip the benefit, experts say.

The cost was set at $20 million and the final bill to cover its initial $5.3 billion cost could be even higher.

But the cost is soaring, and it has already exceeded $30 billion.

It has been estimated that the cost will surpass $40 billion in the next few years, according the government.

And the number of lawsuits is increasing exponentially.

The government’s final estimate is more than double the $10 billion estimate in 2016.

The AP found that since the program was announced last September, more than 3,600 people have been injured and nearly 2,400 died from hypoxia-related illnesses.

And tens of millions of dollars have been spent to settle other lawsuits that could have been avoided.

It also found that in some cases, the program has not only saved lives but has saved money.

The new product has been hailed as a game-changer for people living with respiratory problems and people with heart conditions.

But it has also brought criticism.

The lawsuit filed in August by the American Heart Association and the American Lung Association challenged the safety and effectiveness of the device.

The suits allege the devices use technology designed to detect oxygen saturation and trigger a warning to a user if they fall below a certain level.

The device does not tell the user exactly how much oxygen is in the blood, according Toomey, who said the devices should only be used as a last resort.

If a user does not receive a warning, he said, the user can then return to work, play sports, or work at a desk.

He said the device can also be misused to trigger an alarm.

“It’s a very dangerous product,” Toomeier said.

“People are dying.

It is going to kill more people.”

But others say the device could help people with respiratory conditions who cannot afford the pricey, heart-monitoring device.

“The system that they’re using doesn’t work,” said Dr. Richard J. Bies, chairman of the department of respiratory medicine at the University of Minnesota.

“There are people who are in extreme conditions and people who can’t afford the heart-watch.”

Bies is among those who believe the devices are safe.

The devices use an algorithm to calculate oxygen levels.

If the oxygen is high enough, it triggers an alarm, so the person can be monitored for signs of hypoxemia or stroke.

The manufacturer has been in the midst of developing an algorithm that will help the device distinguish between patients who are hypercapnic or hypoxemic and those who are normal, Bies said.

The algorithm will determine how to treat the user based on their blood oxygen level, and the person will be monitored while they receive oxygen.

Bied also believes the technology has the potential to save lives.

“This device is an absolute game-changing technology,” he said.

Biosolutions.com, a healthcare research firm, said the technology would save more than a million lives each year.

The technology was originally designed for use in cardiac catheterization, or CAT, machines, and is now being used to monitor patients who have a heart problem, said David Poulter, vice president of the firm.

It could also be used to detect heart rhythm abnormalities and to help detect hypoxaemia, which is a condition that results from a lack of oxygen.

“They’re really good at doing something that can save lives,” Poulters said.

Poulers said the use of the technology is in line with what the FDA has approved for use on the market.

The FDA has also approved the use, under a new clinical trial protocol, of a device that detects the blood flow in patients who suffer from pulmonary embolism, a rare condition that involves the clotting of the lungs, he added.

The clinical trial was to determine whether a new sensor could be used safely in patients with pulmonary embollism, he explained.

But in July, the FDA rejected the trial proposal, saying the new sensor was too sensitive to be used in clinical trials.

The trial was set to begin in March, but has been delayed because of the legal problems, Poults said.

Another problem is that some of the sensor devices are not working, Poulster said.

In some cases the sensors can’t detect oxygen, but others don’t work at all, he noted.

“What they’re saying is, ‘We’re going to make the sensors so